Anthralin

Anthralin

SCHEMBL188254

ClC(Cl)Cl.O=C1c2c(O)cccc2Cc2cccc(O)c21

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.85
KMT2A Q03164 5/20 0.85
ALDH1A1 P00352 4/20 0.85
TDP1 Q9NUW8 4/20 0.85
MEN1 O00255 4/20 0.85
USP2 O75604 4/20 0.85
TSHR P16473 3/20 0.85
ALOX15 P16050 3/20 0.85
HSD17B10 Q99714 3/20 0.85
CYP3A4 P08684 3/20 0.85
THRB P10828 2/20 0.85
HPN P05981 1/20 0.85
ALOX5 P09917 1/20 0.85
PTGS1 P23219 1/20 0.85
PDE4A P27815 1/20 0.85
KDR P35968 1/20 0.85
SIRT5 Q9NXA8 1/20 0.85
L3MBTL1 Q9Y468 1/20 0.85
HRH3 Q9Y5N1 1/20 0.85
TNF P01375 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthralin SCHEMBL30013383 0.92 MAPT (1.00) MAPTKMT2AALDH1A1TDP1MEN1
Anthralin SCHEMBL29439039 0.92 MAPT (1.00) MAPTKMT2AALDH1A1TDP1MEN1
Anthralin SCHEMBL3197 0.92 MAPT (1.00) MAPTKMT2AALDH1A1TDP1MEN1
Anthralin SCHEMBL7555831 0.90 MAPT (0.96) MAPTKMT2AALDH1A1TDP1MEN1
Anthralin SCHEMBL5555097 0.81 MAPT (0.71) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL29549838 0.79 MAPT (0.75) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL1204733 0.79 MAPT (0.75) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL12023167 0.79 ALDH1A1 (0.74) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL11208428 0.78 MAPT (0.66) MAPTKMT2AALDH1A1TDP1MEN1
SCHEMBL31509436 0.78 ALDH1A1 (0.71) MAPTKMT2AALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402307-B1 HYDROGELLING AGENT RITSUMEIKAN TRUST (JP) 2016-12-21 EP disclosed
US-8633022-B2 Dual-terminal amide hydrogelling agent THE RITSUMEIKAN TRUST (JP) 2014-01-21 US disclosed
EP-2402307-A1 DUAL-TERMINAL AMIDE HYDROGELLING AGENT The Ritsumeikan Trust (JP) 2012-01-04 EP disclosed
US-20110312092-A1 DUAL-TERMINAL AMIDE HYDROGELLING AGENT ASAHI KASEI KABUSHIKI KAISHA (JP) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312092-A1 DUAL-TERMINAL AMIDE HYDROGELLING AGENT H1-2, H1-0, H1-4 MAPT 3665/4885KMT2A 446/4885ALDH1A1 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.